CLGN — Collplant Biotechnologies Income Statement
0.000.00%
Last trade - 00:00- $20.85m
- $8.94m
- $0.52m
Annual income statement for Collplant Biotechnologies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6.14 | 15.6 | 0.299 | 11 | 0.515 |
| Cost of Revenue | |||||
| Gross Profit | 3.13 | 14 | 0.195 | 9.83 | -0.824 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 11.7 | 15.6 | 17.4 | 18.5 | 17.8 |
| Operating Profit | -5.6 | 0.065 | -17.1 | -7.51 | -17.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.77 | 0.237 | -16.9 | -7.02 | -16.6 |
| Net Income After Taxes | -5.77 | 0.237 | -16.9 | -7.02 | -16.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.77 | 0.237 | -16.9 | -7.02 | -16.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.77 | 0.237 | -16.9 | -7.02 | -16.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.838 | 0.053 | -1.51 | -0.533 | -1.42 |